

# Resource Summary Report

Generated by [kravitz2](#) on Sep 4, 2026

## Coronavirus Immunotherapy Consortium

RRID:SCR\_018258

Type: Tool

### Proper Citation

Coronavirus Immunotherapy Consortium (RRID:SCR\_018258)

### Resource Information

**URL:** <https://covic.lji.org/>

**Proper Citation:** Coronavirus Immunotherapy Consortium (RRID:SCR\_018258)

**Description:** Consortium to unite efforts and resources from experts across globe to advance effective, antibody based therapies against novel coronavirus, SARS-CoV-2. Represents multidisciplinary convergence of structural biology, virologists, immunologists, clinicians and bioinformaticians from academic and industry settings. Collects antibodies for testing as part of CoVICS. Contributed antibodies are blinded and will only be known as code name. Antibody contributors will be able to see performance of their own molecules and take part in analysis. Contributors retain ownership of their antibodies and may continue to publish on them using original antibody names. Goal is to determine relative in vitro potency and in vivo efficacy using centralized standardized assays to identify best individual mAbs and rational combinations of mAbs. Consortium will recommend ideal therapeutic molecules for human use to protect vulnerable populations from COVID-19 disease. CoVIC database (CoVIC-DB) will serve as clearinghouse for monoclonal antibodies against SARS-CoV-2. Database will catalog contributed antibodies in searchable resource and provide interactive analysis tools for comparisons among them.

**Abbreviations:** CoVIC

**Resource Type:** consortium, data or information resource, organization portal, portal, topical portal

**Keywords:** COVID-19, antibody, antibody based therapy, coronavirus, SARS-CoV-2, antibody collection, analysis, potency in vitro, efficacy in vivo, standardized assay, identify mAb, therapeutic molecule, vulnerable population protect, database, data

**Related Condition:** COVID-19

**Availability:** Free, Freely available

**Resource Name:** Coronavirus Immunotherapy Consortium

**Resource ID:** SCR\_018258

**Record Creation Time:** 20220129T080339+0000

**Record Last Update:** 20260903T235814+0000

---

## Ratings and Alerts

No rating or validation information has been found for Coronavirus Immunotherapy Consortium.

No alerts have been found for Coronavirus Immunotherapy Consortium.

---

## Data and Source Information

**Source:** [SciCrunch Registry](#)

---

## Usage and Citation Metrics

We found 14 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [kravitz2](#) .

Kuzmina NA, et al. (2026) SARS-CoV-2 antibody-dependent enhancement of infection depends on antibody binding to both ACE2 and Fc receptors. JCI insight, 11(4).

Schendel SL, et al. (2025) A global collaboration for systematic analysis of broad-ranging antibodies against the SARS-CoV-2 spike protein. Cell reports, 44(4), 115499.

Keitany GJ, et al. (2023) Multimodal, broadly neutralizing antibodies against SARS-CoV-2 identified by high-throughput native pairing of BCRs from bulk B cells. Cell chemical biology, 30(11), 1377.

Callaway HM, et al. (2023) Bivalent intra-spike binding provides durability against emergent Omicron lineages: Results from a global consortium. Cell reports, 42(1), 112014.

Wayham NP, et al. (2023) A Potent Recombinant Polyclonal Antibody Therapeutic for Protection Against New Severe Acute Respiratory Syndrome Coronavirus 2 Variants of Concern. The Journal of infectious diseases, 228(5), 555.

Castro Dopico X, et al. (2022) Immunity to SARS-CoV-2 induced by infection or vaccination. Journal of internal medicine, 291(1), 32.

Yuan TZ, et al. (2022) Rapid discovery of diverse neutralizing SARS-CoV-2 antibodies from large-scale synthetic phage libraries. mAbs, 14(1), 2002236.

Ferrara F, et al. (2022) A pandemic-enabled comparison of discovery platforms demonstrates a naïve antibody library can match the best immune-sourced antibodies. *Nature communications*, 13(1), 462.

Yan W, et al. (2022) Structural biology of SARS-CoV-2: open the door for novel therapies. *Signal transduction and targeted therapy*, 7(1), 26.

Cho H, et al. (2021) Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern. *Science translational medicine*, 13(616), eabj5413.

Cho H, et al. (2021) Ultrapotent bispecific antibodies neutralize emerging SARS-CoV-2 variants. *bioRxiv : the preprint server for biology*.

Hastie KM, et al. (2021) Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: A global consortium study. *Science (New York, N.Y.)*, 374(6566), 472.

DeFrancesco L, et al. (2020) COVID-19 antibodies on trial. *Nature biotechnology*, 38(11), 1242.

Arturo EC, et al. (2020) Lifted Up from Lockdown. *Cell*, 183(1), 1.